Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Operating Leases (2019 - 2025)

Celldex Therapeutics (CLDX) has 7 years of Operating Leases data on record, last reported at $784000.0 in Q4 2025.

  • For Q4 2025, Operating Leases fell 66.79% year-over-year to $784000.0; the TTM value through Dec 2025 reached $784000.0, down 66.79%, while the annual FY2025 figure was $784000.0, 66.79% down from the prior year.
  • Operating Leases reached $784000.0 in Q4 2025 per CLDX's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.6 million in Q4 2022 and bottomed at $470000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $1.6 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Operating Leases: crashed 78.21% in 2024, then skyrocketed 310.43% in 2025.
  • A 5-year view of Operating Leases shows it stood at $1.3 million in 2021, then skyrocketed by 99.69% to $2.6 million in 2022, then tumbled by 64.14% to $928000.0 in 2023, then soared by 154.42% to $2.4 million in 2024, then plummeted by 66.79% to $784000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $784000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.5 million in Q2 2025.